Myeloid-derived suppressor cells (MDSCs) depletion by cabozantinib improves the efficacy of anti-HER2 antibody-based immunotherapy in a 4T1-HER2 murine breast cancer model
Vahid Khaki Bakhtiarvand, Khadijeh Ramezani-Ali Akbari, Seyed Amir Jalali, Mohammad Hojjat‐Farsangi, Mahmood Jeddi‐Tehrani, Fazel Shokri, Mahdi Shabani
Topics & Concepts
CabozantinibMyeloid-derived Suppressor CellMedicineImmunotherapyCancer researchBreast cancerPopulationMonoclonal antibodyAntibodyTumor microenvironmentMyeloidImmunologyCytokineImmune systemCancerInternal medicineSuppressorEnvironmental healthImmune cells in cancerPhagocytosis and Immune RegulationImmune responses and vaccinations